Member Info for Jonah58

TBT. Obviously we need to know the details. I'm pretty sure Amplatz don't process any of our material. There is an inherent problem with smelters going into meltdown when handling chromite ore, it has happened before. And, incidentally, this problem is avoided using the Conroast recipe which, by my calculations, should be coming out of patent any time now!
I don't think we can blame LC for this one.

Master. I think that's history now. My strong impression is that vanadium is on hold for the time being due to falling prices.

There was a slightly pompous poster on here last year (forgotten the name) talking up vanadium and the new regulations in Chine re rebar composition. Maybe vanadium will bounce back as it also has applications in batteries.

Good luck with your investments Speedie. I'm not watching too closely at the moment, it's slightly depressing. Need to wait for the mass hysteria to settle.

In some interview or RNS a while back, it was made clear that Sable would be developed in a way that permitted easy switching from copper to zinc according to ambient commodity prices. We are still building the zinc facility, so no marked deviation from stated policy there. Lead has always come later. I would say everything is still going to plan except for vanadium, which, according to LC, has a short lead in time so we can put that on hold, and develop a circuit quickly at a later date if it looks economic..
And, while we are at it, I don't see Covid as a market catastrophe in the making. A set back, yes, but China's new cases and mortality are not increasing exponentially, as some predicted. In fact they are dropping back markedly and, economically speaking, where China goes, we all follow. I'm back in.

There already is a vaccine and more will follow shortly. I predict something effective will be available in July at the latest.

Respect your opinion, TbT but not sure that I agree.Zinc and Vanadium are not too strong at the moment and the lead circuit is the last one planned. I suspect JLP is putting more effort into the copper and cobalt side at the moment, ready to move over to the tailings when the market improves. No need to invoke any more horrors to explain this modest retrace.
Platinum holding above 900 and both palladium and rhodium ploughing on. I sold a few when the coronavirus started closing things down, but will be buying back today. Ever the optimist.

RNS link does not work for me. Read it here: https://www.investegate.co.uk/polo-resources-ltd--pol-/rns/hibiscus-petroleum---investment-update/202002260700021130E/

Hibiscus continuing to deliver.

Neither Nolupus or anyone else can predict how long it's going to take to recruit patients for the P3 trial. That depends on how many patients are needed to power the endpoints, the entry criteria, how many recruitment centres are set up, and the rate of recruitment at each centre. We just have to be patient. Some sort of clarity should emetge fairly soon though.

Hi Visitor. Appreciate your post. Can you reassure us that, in your calculations, there is no mix up between JLP's revenue from PGM Concentrate (prior to smelting and refining) versus quoted basket price for PGM Metal? I know most of the value is in the concentrate, but this issue has been overlooked in a number of posts on this topic over the last few months.

Jazzer, the issue resides with your 'If'. Yes, if the honourable Datuk delivers on GCM it would be fantastic for Polo shareholders, but he hasn't delivered so far and the market doesn't seem to think he will deliver any time soon, (at a time when sentiment worldwide could not be more hostile towards the burning of fossil fuels). Since taking over from Dattels (who took shareholders' interests very seriously) he has bought with our money some phoney Indonesian coal venture (still waiting for some of that back), an Australian gold outfit with a boardroom spat and unexpectedly low grades of ore, a copper company whose leaching pads have been inundated with water and has gone bust and a Tunisian phopsphate company just before their venture partners absconded with all the whole kaboodle. We are still propping this one up with more cash and undertaking certain other transactions which a large shareholder is objecting to (see letter from Phronimos). The iron ore/vanadium/lithium play in Canada is moving desperatley slowly. Admittedly, he was not to blame for Ebola virus in Siera Leone where we have written off a gold mine and been diddled out of another load of cash by some company in the Channel Islands. He HAS made a sound investment in Hibiscus, but it is hardly surprising that sentiment is at an all time low which is why we are trading at a fraction of our NAV. For this reason, a large group of shareholders are not unreasonably fed up and rather than sit for another eternity watching the honourable Datuk enjoying his magnificent salary are proposing that the assets should be realised as they stand and distributed to the exhausted folk who have kept the ship afloat all these years since Dattels left. So, for us, GCM is just part of the story. All will be forgiven, however, if Phulbari ever getas the green light

breaks through $10,000

www.phronimoscap.com/news

OK Mcco. It's Phronimos. Sam John has written to the AIM regulators on behalf of private investors complaining in the strongest possible terms about the voting at the recent AGM. His letter is long and detailed and, although in the public domain, too long to cut and paste here. He objects that certain shares (Armstrong) were disenfranchised on a technicality, and that related party shareholdings have been manipulated. More specifically, he claims that Diyani is a related party and the issuance of shares to them at a discount was a deliberate manipulation contrary to good corporate governance. He has requested that these shares are not admitted for dealing until an investigation has been completed.

I am sure any bona fide peep who contact Phronimos would get a copy of the letter.

You have touched on an important point NoEx. Of course, new material will continue to be dumped provided Samancor keep Inyoni going, but the volumes will be much less than currently available. Ditto third party ore at Windsor. I have speculated that we could possibly truck in concentrate from ASA but it's a long way. On several occasions I have expressed concern that the longevity of our projects seems to be enough to repay capex plus loans, keep the company afloat and pay the wages without much left for the shareholders. We are reliant on new projects coming on-line., and I do get the impression that the BoD are always on the look out for opportunities and quick to act when they crop up. Kabwe is huge and should last a good long time. I am anticipating another project in Zambia and would not be surprised if we changed stance to take a significant position in copper and cobalt.
Another possibility is that we get into bed with one of the majors, taking on their PGM reprocessing (we are already sort of doing that with Northam). Finally, we need to see what happens to the basket price of PGMs. It is not inconceivable that, at some stage, Tjate will also come into play as some sort of joint venture.

No idea why, Mc. It's unusual for this to happen. Might ask the good folk on GCM if they have any idea.

Bit of activity on GCM today, but has all the makings of yet another P&D!

Quiet here so please excuse off-topic. I mentioned Poxel a while ago. Done well since. I'm currently researching Evelo (a US bio/pharma). Very interesting science. Sp has been up and down. Thought I'd share this. Please don't ******* me for off topic. Neither of these shares has a board on LSE. No hidden agenda, though I've taken a small position in both.

Completely lost touch with this share. Wrote it off 2 years ago. Do we still have any interest in RMP?

Now, there's a thought Newby

So, as predicted, we now own 27% GCM at a time when sentiment worldwide against the use of fossil fuels could not be higher. Interested to note, however, that a statement about the adjourned AGM will be made 'soon'.

Agree with Marie. This is more or less the time scale predicted on this board some time ago. It is nice, however, to have it confirmed. I can't wait to see the details of recruitment, entry criteria and end points which look as though they might be available in Q2 - so soon. Once we know how many patients are going to be recruited and the number of centres, we can speculate sensibly about the length of the trial ( by which I mean the time from recruiting the first patient to reporting headline results).